Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELEV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELEVElevation Oncology$0.25-5.4%$0.54$0.24▼$5.83$14.63M1.371.34 million shs625,392 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELEVElevation Oncology-0.35%-10.66%-50.54%-53.95%-94.95%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELEVElevation Oncology2.6521 of 5 stars4.22.00.00.01.81.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELEVElevation Oncology 2.30Hold$3.391,281.92% UpsideCurrent Analyst Ratings BreakdownLatest ELEV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/24/2025ELEVElevation OncologyStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$5.00 ➝ $1.003/21/2025ELEVElevation OncologyCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform3/21/2025ELEVElevation OncologyLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$9.00 ➝ $1.003/21/2025ELEVElevation OncologyCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform3/21/2025ELEVElevation OncologyPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$10.00 ➝ $0.703/21/2025ELEVElevation OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $1.003/20/2025ELEVElevation OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/20/2025ELEVElevation OncologyLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/10/2025ELEVElevation OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/7/2025ELEVElevation OncologyWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$5.00(Data available from 4/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELEVElevation OncologyN/AN/AN/AN/A$1.29 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELEVElevation Oncology-$45.70M-$0.81N/AN/AN/AN/A-59.73%-40.05%5/1/2025 (Estimated)Latest ELEV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/6/2025Q4 2024ELEVElevation Oncology-$0.22-$0.18+$0.04-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELEVElevation OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELEVElevation Oncology0.4517.7717.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELEVElevation Oncology83.70%Insider OwnershipCompanyInsider OwnershipELEVElevation Oncology8.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELEVElevation Oncology4059.22 million54.33 millionOptionableELEV HeadlinesRecent News About These CompaniesStephens Reaffirms "Equal Weight" Rating for Elevation Oncology (NASDAQ:ELEV)March 26, 2025 | americanbankingnews.comElevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025March 25, 2025 | prnewswire.comStephens & Co. Downgrades Elevation Oncology (ELEV)March 25, 2025 | msn.comAnalysts Issue Forecasts for ELEV FY2029 EarningsMarch 25, 2025 | americanbankingnews.comElevation Oncology Terminates CLDN18.2-Targeted ADC, Reduces WorkforceMarch 24, 2025 | precisionmedicineonline.comElevation Oncology downgraded to Equal Weight from Overweight at StephensMarch 24, 2025 | markets.businessinsider.comElevation Oncology, Inc. (NASDAQ:ELEV) Receives $6.83 Average Target Price from AnalystsMarch 24, 2025 | americanbankingnews.comElevation Oncology (NASDAQ:ELEV) Lowered to Market Perform Rating by Leerink PartnersMarch 24, 2025 | americanbankingnews.comElevation Oncology (NASDAQ:ELEV) Stock Rating Lowered by Piper SandlerMarch 24, 2025 | americanbankingnews.comHC Wainwright Cuts Elevation Oncology (NASDAQ:ELEV) Price Target to $1.00March 24, 2025 | americanbankingnews.comElevation Oncology (NASDAQ:ELEV) Lowered to "Market Perform" Rating by Citizens JmpMarch 23, 2025 | americanbankingnews.comElevation Oncology (NASDAQ:ELEV) Stock Rating Lowered by WedbushMarch 23, 2025 | americanbankingnews.comElevation Oncology to discontinue development of EO-3021, a Claudin 18.2 ADC to treat advanced unresectable or metastatic gastric and GEJMarch 22, 2025 | pharmabiz.comCitizens Capital Markets Downgrades Elevation Oncology (ELEV)March 22, 2025 | msn.comLeerink Partners Downgrades Elevation Oncology (ELEV)March 21, 2025 | msn.comElevation Oncology downgraded to Market Perform from Outperform at Citizens JMPMarch 21, 2025 | markets.businessinsider.comElevation Oncology price target lowered to $1 from $6 at H.C. WainwrightMarch 21, 2025 | markets.businessinsider.comElevation Oncology Plunges 42% on Ending Development of Lead DrugMarch 21, 2025 | zacks.comElevation Oncology (NASDAQ:ELEV) Stock, Short Interest ReportMarch 21, 2025 | benzinga.comElevation Oncology downgraded as it halts lead asset on disappointing trialsMarch 21, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWarren Buffett Swaps VOO for This Reliable Dividend StockBy Sarah Horvath | March 7, 2025View Warren Buffett Swaps VOO for This Reliable Dividend StockNVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBy Thomas Hughes | March 12, 2025View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?By Jeffrey Neal Johnson | March 21, 2025View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?3 Defense Stocks Set to Benefit From Increased Military SpendingBy Chris Markoch | March 20, 2025View 3 Defense Stocks Set to Benefit From Increased Military SpendingWhich Healthcare Stock Is the Best Buy Right Now?By Nathan Reiff | March 31, 2025View Which Healthcare Stock Is the Best Buy Right Now?ELEV Company DescriptionsElevation Oncology NASDAQ:ELEV$0.24 -0.01 (-5.44%) As of 03:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy Amazon Falls Back to a Key Support Line: Here's How to Play It Berkshire Hathaway Gains Defy Stock Market Slump Tech Sell-Off Makes Microsoft Stock Look Like a Steal Palantir Stock Builds Momentum on New Partnership Amprius Market Gets Amped Up on Growth Outlook 3 Buyable Stocks With Solid Bottoms Ready to Rebound Game-Changing News for Advanced Micro Devices Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
